The EVERY Company has agreed a manufacturing expansion with Bulgarian pharmaceutical group Huvepharma that will quadruple production capacity for OvoPro, its precision-fermented ovalbumin protein, following a period of sharp commercial growth.
The agreement tasks Huvepharma’s manufacturing subsidiary, Biovet AD, with scaling output at its fermentation sites in Bulgaria, which hold over 9 million litres of installed fermentation capacity. According to the company, EVERY recorded annual orders in the first four months of 2026 worth 550% of its total 2025 order volume, driven by national retail placement in Target and Walmart alongside growing demand from e-commerce and foodservice customers.
Bulgarian infrastructure at the core
Biovet AD operates three fermentation facilities across Bulgaria, in Peshtera, Razgrad, and Botevgrad, and holds GMP approvals from both the EU and the US FDA. The expanded partnership will leverage this infrastructure to produce OvoPro at industrial volumes, with the company stating it is already shipping metric tons to customers on a steady-state basis.
Arturo Elizondo, CEO and co-founder of The EVERY Company, stated, “Scaling to meet the world’s appetite for consistent, stable protein requires more than just great science; it requires world-class manufacturing partners. Huvepharma has been an instrumental partner in our journey from the bench to industrial scale. Quadrupling our capacity today is a direct response to the market’s clear signal: the food industry is ready for egg proteins that deliver parity on performance without the supply chain challenges endemic in the global egg supply chain.”
OvoPro is a pure ovalbumin protein that replicates the binding, foaming, and texturizing properties of conventional egg white in applications including baked goods, bars, snacks, confections, and pasta. It is shelf-stable for up to 24 months and does not require cold-chain logistics, which EVERY cites as a key advantage over conventional egg supply for food manufacturers.
Commercial context
The EVERY Company, founded in 2014 as Clara Foods, has raised over $288 million to date, including a $55 million Series D closed in late 2025. That round was directed toward expanding manufacturing capacity and reaching profitability. The company’s ingredients have also attracted partnerships with Grupo Nutresa and The Vegetarian Butcher, among others.
Anguel Jeliazkov, Chief Executive Director of Biovet AD, noted, “Biovet’s fermentation infrastructure serves customers across more than 100 countries. Bringing that capacity to EVERY’s protein platform is a natural extension of what we do. We do not just scale processes — we industrialise them. That is the value we bring to this partnership, and the results so far demonstrate it clearly.”
